Sankar Sundaram and Shubhankar Joshi
Accepted Abstracts: Pharmaceut Reg Affairs
It is becoming harder and harder to discover a new Drug. A part could be attributed to ?the low-hanging fruits have already been plucked? maxim and another part to the huge expenses involved in the design, synthesis, preclinical and clinical evaluation of a new therapeutic intervention. It is therefore, desirable to reduce the cost of Drug Discovery by adopting low-cost outsourcing of custom-synthesis, cost-effective and sure-shot screening methods, bedrock Safety-profiling etc. Before committing one?s resources to the above Business development strategy, it is advisable to thoroughly estimate the elbow room available under one?s command. Enter the Patent and XP Documents, whose gleaning, determines the first step in ascertaining the metes and bounds of business risk propensity. A few case studies are being discussed, to get an insight of smarter staking in the realm of New Drug Development business.
Sankar Sundaram, the son of a Registered Nurse, has completed his PhD in Pharmaceutical Sciences, from The Tamil Nadu Dr MGR Medical University and Bachelor of General Laws? from the Annamalai University. He is a Registered Patent agent (IN/PA-666) in the Indian Intellectual Property Office and has drafted more than fifteen patents pertaining to the field of Pharmaceutical Products. Currently, he is guiding PhD scholars in New Drug Discovery and is teaching Medicinal Chemistry for graduate students at the JSS University, Mysore.
Pharmaceutical Regulatory Affairs: Open Access received 533 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 